An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A PHASE3 clinical study on Neuralgia and Pain, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 8 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beppu, Japan , Bibai, Japan , Bunkyo-ku, Japan , Chikushi-gun, Japan , Daisen, Japan , Fukuyama, Japan , Hakodate, Japan , Hanamaki, Japan , Higashiokitama-gun, Japan , Iizuka, Japan and 13 more locations